Jasper Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 16, 2021 and accepted by EDGAR at Aug 16, 2021, 17:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$562.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$776.4k | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$3.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | $1.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$678.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-06-30 | $309.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $422.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $100.5m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $328.9k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $14.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-21-043115. Last ingested by Listed: Nov 9, 2026, 17:50 ET. Listed shows no prices and gives no investment advice.